SPI
SUPN icon

Santori & Peters Inc’s Supernus Pharmaceuticals SUPN Stock Holding History

Santori & Peters Inc’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-130
Closed -$4K – 462
2017
Q4 		$4K Buy
+130
New +$5.14K ﹤0.01% 495

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Santori & Peters Inc's SUPN Position: Q1 2018 in Review

Santori & Peters Inc sold out of Supernus Pharmaceuticals (SUPN) in Q1 2018, closing a stake of 130 shares — an estimated $4K sold.

Santori & Peters Inc first reported a position in SUPN in Q4 2017 and held it in 1 quarter. The position peaked at $4K in Q4 2017. 312 funds tracked by Wall St. Rank hold SUPN as of Q1 2018.

  • Santori & Peters Inc reported no remaining Supernus Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Santori & Peters Inc sold 130 Supernus Pharmaceuticals shares in Q1 2018, an estimated $4K.
  • Santori & Peters Inc first reported a position in Supernus Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Santori & Peters Inc's Supernus Pharmaceuticals position peaked at $4K in Q4 2017.
  • 312 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2018.

Based on Santori & Peters Inc's 13F filing for Q1 2018, filed 16 Apr 2018.